Trial reportEuropean archives of psychiatry and clinical neuroscience2007
Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.
Trial report in European archives of psychiatry and clinical neuroscience, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 6 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Impact of selected second and third generation antipsychotics on cognitive dysfunction in schizophrenia-spectrum disorders. Systematic review and network meta-analysis.International clinical psychopharmacology · 2026Pooled it
- Almost all antipsychotics result in weight gain: a meta-analysis.PloS one · 2014 · on this mapPooled it
- Quetiapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2013Pooled it
- Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.Drug safety · 2012Pooled it
- Olanzapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2010Pooled it
- Quetiapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2010Pooled it
- Social skills and neurocognitive individualized training in schizophrenia: comparison with structured leisure activities.European archives of psychiatry and clinical neuroscience · 2010Trial
- Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics.European archives of psychiatry and clinical neuroscience · 2008Trial
- Short-term Medication Effects on Brain Functional Activity and Network Architecture in First-Episode psychosis: a longitudinal fMRI study.Brain imaging and behavior · 2023Article
- Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".Neuropsychopharmacology reports · 2021Article
- Polygenic analysis suggests the involvement of calcium signaling in executive function in schizophrenia patients.European archives of psychiatry and clinical neuroscience · 2020Article
- A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future.Neuropsychiatric disease and treatment · 2019Article
- Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist-physician collaboration in the outpatient department.Integrated pharmacy research & practice · 2018Article
- Response to: A Commentary on "Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders".Frontiers in behavioral neuroscience · 2015Article
- Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments.Neuropharmacology · 2012Review
- Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats.Psychopharmacology · 2012Article
- The influence of switching from oral risperidone to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.Therapeutic advances in psychopharmacology · 2012Article
- Quetiapine and Buspirone Both Elevate Cortical Levels of Noradrenaline and Dopamine In vivo, but Do Not have Synergistic Effects.Frontiers in psychiatry · 2012Article
- The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia.BMC psychiatry · 2010Article
- [Cognitive disorders in schizophrenic patients].Der Nervenarzt · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurocognitive impairment is a core feature in the pathology of schizophrenia and considered to be relatively persistent towards psychopharmacological interventions. There are hints that atypical antipsychotics can influence neurocognitive dysfunctions more favorable than conventional compounds. But little is known about differences in efficacy on neurocognitive dysfunctions linked to the variety of receptor profiles of different atypical antipsychotics. This study compared the effects of the atypical antipsychotics quetiapine and olanzapine on cognitive function in patients with an acute episode of schizophrenia. Patients were randomized to receive quetiapine or olanzapine for 8 weeks. Cognitive function was assessed at baseline, week 4 and week 8. Efficacy was assessed weekly using the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Improvement Scale (CGI). Tolerability was assessed each week using the Extrapyramidal Symptom Rating Scale (ESRS), the Barnes Akathisia Scale (BAS) and the Udvalg for Kliniske Undersogelser Side Effect Rating Scale (UKU). In total, 52 patients were enrolled in the study. Data from the 33 patients who completed cognitive assessments at two or more time points out of three (baseline, Week 4 and Week 8) are analyzed here. Both quetiapine and olanzapine improved global cognitive index z-scores, however, this was more marked with quetiapine. Between-group comparisons showed significantly greater improvements in reaction quality/attention with quetiapine than olanzapine. Quetiapine and olanzapine produced significant improvements from baseline to week 8 in PANSS total and subscale scores. Both treatments were well tolerated, especially no EPS occurred during 8 weeks of treatment. Both quetiapine and olanzapine improved cognition; however, the improvement in cognitive index scores was more marked in patients receiving quetiapine. Furthermore, quetiapine produced a significantly greater improvement in reaction quality/attention than olanzapine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.